Journal of Diabetes Research / 2019 / Article / Tab 2

Review Article

Angiopoietins in Diabetic Retinopathy: Current Understanding and Therapeutic Potential

Table 2

Overview of agents targeting the Ang/Tie2 pathway that are currently in clinical development.

Drug nameDeveloperTargetTrial phaseIndicationPatients enrolledControlPrimary outcome measureResult

AKB-9778Akebia TherapeuticsVE-PTPIIbDMO167PlaceboDRSSFailed
REGN910-3RegeneronAng2 and VEGFIIDMO301AfliberceptBCVAFailed
RG-7716Roche GenentechAng2 and VEGFIIDMO230Low-dose ranibizumabBCVASuccess

DRSS = diabetic retinopathy severity score; BCVA = best-corrected visual acuity.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.